In order to clinically develop the BCR-ABL degraders, it is important to examine the protein knockdown and anti-proliferation activities in primary CML cells and CD34+ stem cells, which allows us to estimate the on- and off-target effects. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.